Compare UTHR & DUOL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UTHR | DUOL |
|---|---|---|
| Founded | 1996 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.3B | 8.8B |
| IPO Year | 1999 | 2021 |
| Metric | UTHR | DUOL |
|---|---|---|
| Price | $489.62 | $199.63 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 17 |
| Target Price | ★ $495.08 | $330.67 |
| AVG Volume (30 Days) | 424.3K | ★ 2.0M |
| Earning Date | 10-29-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 16.08 | ★ 338.81 |
| EPS | ★ 26.38 | 8.04 |
| Revenue | ★ $3,128,400,000.00 | $964,271,000.00 |
| Revenue This Year | $13.64 | $40.50 |
| Revenue Next Year | $5.78 | $22.65 |
| P/E Ratio | ★ $18.55 | $24.86 |
| Revenue Growth | 13.50 | ★ 39.86 |
| 52 Week Low | $266.98 | $166.27 |
| 52 Week High | $492.62 | $544.93 |
| Indicator | UTHR | DUOL |
|---|---|---|
| Relative Strength Index (RSI) | 68.10 | 44.78 |
| Support Level | $470.13 | $181.20 |
| Resistance Level | $492.62 | $194.20 |
| Average True Range (ATR) | 10.72 | 8.61 |
| MACD | -0.53 | 6.46 |
| Stochastic Oscillator | 89.55 | 93.92 |
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
Duolingo Inc is a technology company that develops a mobile learning platform to learn languages and is the top-grossing app in the Education category on both Google Play and the Apple App Store. Its products are powered by sophisticated data analytics and artificial intelligence and delivered with class art, animation, and design to make it easier for learners to stay motivated master new material, and achieve their learning goals. Its solutions include the Duolingo Language Learning App, Super Duolingo, Duolingo English Test: AI-Driven Language Assessment, Duolingo For Schools, Duolingo ABC, and Duolingo Math. It has four predominant sources of revenue; time-based subscriptions, in-app advertising placement by third parties, and the Duolingo English Test, and In-App Purchases.